Donate

First Patient Dosed in Phase 3 of Study in Patients with Severe Hemophilia A

December 12, 2019

The following is an excerpt from a press release from Sanofi Genzyme. Read the press release in its entirety here. Sanofi and SobiTM聽announced the first patient has been dosed in the Phase 3, open-label, interventional study of BIVV001 (rFVIIIFc-VWF-XTEN), in patients with severe hemophilia A (XTEND-1 study; NCT04161495). Sobi and Sanofi are development partners for […]

Sanofi Genzyme Launches Innovative and Educational Audio Adventure Series for People Treated with ALPROLIX庐

March 15, 2019

The following is a press release from Sanofi Genzyme. Find the full press release here. Sanofi Genzyme, the specialty care business unit of Sanofi, announced the launch of a first-of-its-kind audio adventure series designed to provide an engaging and educational infusion experience for ALPROLIX庐 [Coagulation Factor IX (Recombinant), Fc Fusion Protein] patients and their caregivers. […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.